OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 26.83 Million CAD | -61.14% |
| 2022 | 69.04 Million CAD | -6.96% |
| 2021 | 74.21 Million CAD | -37.16% |
| 2020 | 118.09 Million CAD | 16.33% |
| 2019 | 101.51 Million CAD | -13.95% |
| 2018 | 117.97 Million CAD | 1106.68% |
| 2017 | 9.77 Million CAD | 1.77% |
| 2016 | 9.6 Million CAD | 51.96% |
| 2015 | 6.32 Million CAD | 5376.33% |
| 2014 | 115.44 Thousand CAD | 58.23% |
| 2013 | 72.95 Thousand CAD | 84.38% |
| 2012 | 39.57 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 41.18 Million CAD | 53.51% |
| 2024 Q3 | 58.89 Million CAD | -1.82% |
| 2024 Q2 | 59.98 Million CAD | 45.62% |
| 2023 Q3 | 46.52 Million CAD | 9.12% |
| 2023 Q1 | 57.98 Million CAD | -16.03% |
| 2023 Q2 | 42.63 Million CAD | -26.46% |
| 2023 FY | 26.83 Million CAD | -61.14% |
| 2023 Q4 | 26.83 Million CAD | -42.33% |
| 2022 Q1 | 62.68 Million CAD | -15.54% |
| 2022 Q2 | 71.71 Million CAD | 14.42% |
| 2022 Q3 | 72.2 Million CAD | 0.68% |
| 2022 FY | 69.04 Million CAD | -6.96% |
| 2022 Q4 | 69.04 Million CAD | -4.37% |
| 2021 Q2 | 125.53 Million CAD | -18.86% |
| 2021 Q3 | 73.53 Million CAD | -41.42% |
| 2021 Q4 | 74.21 Million CAD | 0.92% |
| 2021 FY | 74.21 Million CAD | -37.16% |
| 2021 Q1 | 154.71 Million CAD | 31.01% |
| 2020 Q3 | 113.51 Million CAD | -8.58% |
| 2020 Q2 | 124.17 Million CAD | -11.72% |
| 2020 Q1 | 140.66 Million CAD | 38.56% |
| 2020 Q4 | 118.09 Million CAD | 4.03% |
| 2020 FY | 118.09 Million CAD | 16.33% |
| 2019 Q4 | 101.51 Million CAD | 10.82% |
| 2019 FY | 101.51 Million CAD | -13.95% |
| 2019 Q3 | 91.61 Million CAD | -7.71% |
| 2019 Q2 | 99.26 Million CAD | -26.83% |
| 2019 Q1 | 135.66 Million CAD | 14.99% |
| 2018 Q4 | 117.97 Million CAD | 9.88% |
| 2018 FY | 117.97 Million CAD | 1106.68% |
| 2018 Q1 | 10.06 Million CAD | 2.94% |
| 2018 Q2 | 107.99 Million CAD | 973.13% |
| 2018 Q3 | 107.36 Million CAD | -0.59% |
| 2017 Q1 | 6.85 Million CAD | -28.7% |
| 2017 Q2 | 8.5 Million CAD | 24.09% |
| 2017 FY | 9.77 Million CAD | 1.77% |
| 2017 Q3 | 7.22 Million CAD | -14.99% |
| 2017 Q4 | 9.77 Million CAD | 35.3% |
| 2016 FY | 9.6 Million CAD | 51.96% |
| 2016 Q3 | 9.89 Million CAD | 5.12% |
| 2016 Q2 | 9.41 Million CAD | 10.02% |
| 2016 Q1 | 8.55 Million CAD | 35.33% |
| 2016 Q4 | 9.6 Million CAD | -2.91% |
| 2015 Q1 | 3.42 Million CAD | 213.85% |
| 2015 FY | 6.32 Million CAD | 5376.33% |
| 2015 Q4 | 6.32 Million CAD | 46.13% |
| 2015 Q3 | 4.32 Million CAD | -2.77% |
| 2015 Q2 | 4.44 Million CAD | 29.83% |
| 2014 Q1 | 80.74 Thousand CAD | 16.13% |
| 2014 Q3 | 115.44 Thousand CAD | 20.05% |
| 2014 Q4 | 1.09 Million CAD | 845.89% |
| 2014 Q2 | 96.16 Thousand CAD | 19.1% |
| 2014 FY | 115.44 Thousand CAD | 58.23% |
| 2013 Q2 | 70.77 Thousand CAD | 63.85% |
| 2013 Q1 | 43.19 Thousand CAD | 79.63% |
| 2013 FY | 72.95 Thousand CAD | 84.38% |
| 2013 Q4 | 69.52 Thousand CAD | -4.7% |
| 2013 Q3 | 72.95 Thousand CAD | 3.09% |
| 2012 Q4 | 24.04 Thousand CAD | -39.23% |
| 2012 Q3 | 39.57 Thousand CAD | -51.11% |
| 2012 Q2 | 80.93 Thousand CAD | 31.33% |
| 2012 Q1 | 61.63 Thousand CAD | 0.0% |
| 2012 FY | 39.57 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | 72.798% |
| Harrow Health, Inc. | 241.75 Million USD | 88.901% |
| Dynavax Technologies Corporation | 375.02 Million USD | 92.845% |
| Biofrontera Inc. | 23.13 Million USD | -15.96% |
| Cronos Group Inc. | 43.73 Million USD | 38.65% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -206.441% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 96.717% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 44.613% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -27.905% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 48.907% |
| Radius Health, Inc. | 804.29 Million USD | 96.664% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -95.08% |
| DURECT Corporation | 30.4 Million USD | 11.754% |
| ProPhase Labs, Inc. | 42.54 Million USD | 36.931% |
| Safety Shot Inc | 3.89 Million USD | -589.406% |
| Phibro Animal Health Corporation | 725.54 Million USD | 96.302% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -191.76% |
| Alvotech | 1.88 Billion USD | 98.575% |
| Assertio Holdings, Inc. | 148.41 Million USD | 81.921% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 94.496% |
| Rockwell Medical, Inc. | 30.88 Million USD | 13.114% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -337.032% |
| Procaps Group S.A. | 462.06 Million USD | 94.193% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 80.396% |
| SCYNEXIS, Inc. | 55.45 Million USD | 51.61% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 70.312% |
| Viatris Inc. | 27.21 Billion USD | 99.901% |
| OptiNose, Inc. | 194.33 Million USD | 86.193% |
| SIGA Technologies, Inc. | 57.97 Million USD | 53.72% |
| Tilray Brands, Inc. | 892.11 Million USD | 96.992% |
| PetIQ, Inc. | 645.22 Million USD | 95.841% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -337.032% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 97.368% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -611.321% |
| Alimera Sciences, Inc. | 107.35 Million USD | 75.006% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 97.169% |
| Silver Spike Investment Corp. | 3 Million USD | -791.479% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1315.216% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 85.205% |
| Journey Medical Corporation | 56.49 Million USD | 52.509% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -25.879% |
| Alpha Teknova, Inc. | 38.55 Million USD | 30.399% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -281.896% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 87.793% |
| PainReform Ltd. | 2.69 Million USD | -897.101% |
| Cosmos Health Inc. | 30.25 Million USD | 11.307% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 84.525% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -91.356% |
| Embecta Corp. | 2.03 Billion USD | 98.682% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -12123.478% |
| Talphera, Inc. | 6.29 Million USD | -326.582% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 96.19% |
| Incannex Healthcare Limited | 5.83 Million USD | -360.24% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -216.023% |
| Shineco, Inc. | 47.6 Million USD | 43.632% |
| Procaps Group, S.A. | 462.06 Million USD | 94.193% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 94.311% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 83.63% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 96.788% |
| Alvotech | 1.88 Billion USD | 98.575% |
| Hempacco Co., Inc. | 18.82 Million USD | -42.554% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 84.454% |
| Bright Green Corporation | 6.43 Million USD | -316.769% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 95.939% |
| Kamada Ltd. | 109.96 Million USD | 75.6% |
| Indivior PLC | 1.95 Billion USD | 98.625% |
| Evoke Pharma, Inc. | 9.64 Million USD | -178.107% |
| Flora Growth Corp. | 17.22 Million USD | -55.801% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -216.023% |
| Evolus, Inc. | 209.68 Million USD | 87.204% |
| HUTCHMED (China) Limited | 536.38 Million USD | 94.998% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 96.928% |
| Akanda Corp. | 12.66 Million USD | -111.794% |